-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

365 Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial

Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment Decisions
Hematology Disease Topics & Pathways:
Measurable Residual Disease
Saturday, December 7, 2024: 5:00 PM

Noemi Puig, PhD1,2, Bruno Paiva, PhD3,4,5*, María T Cedena6*, Cristina Agullo7*, Teresa Contreras7*, Sergio Castro2*, Ana Maria Sureda Balari, MD, PhD8,9,10,11,12,13,14,15,16,17,18,19, Veronica Gonzalez-Calle, MD, PhD20*, Albert Oriol21,22,23,24*, Enrique M Ocio, MD, PhD25*, Laura Rosiñol Dachs26,27,28,29*, Yolanda González-Montes, MD, PhD30,31*, Joan Bargay32*, Esther González García, MD, PhD33*, Miguel Teodoro Hernández Garcia, MD, PhD34*, Angel Ramirez, MD, PhD35,36*, Alexia Suarez-Cabrera, MD, PhD37*, María-Jesús Blanchard, MD, PhD38*, Sebastián Garzón, MD, PhD39*, Luis Felipe Casado Montero40*, Valentin Cabanas Perianes, MD, PhD41*, Jaime Perez de Oteyza42*, Mercedes Gironella, MD43*, Joaquín Martínez-Lopez44,45*, Pilar Delgado, MD, PhD46*, Elena Prieto, MD, PhD47*, Juan-Jose Lahuerta Palacios, MD, PhD48*, Joan Bladé, MD, PhD49,50,51*, Jesús F. San-Miguel, MD, PhD52,53,54 and Maria- Victoria Mateos1,55,56,57,58,59

1Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain, Salamanca, Spain
2Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), University of Salamanca, Salamanca, Spain
3Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada., Pamplona, Spain
4Cancer Center Clinica Universidad de Navarra (CCUN)., Pamplona, Spain
5Clinica Universidad de Navarra (CCUN), Center for Applied Medical Research (CIMA), IDISNA, CIBER-ONC, Pamplona, Spain
6University Hospital 12 de octubre, Madrid, Spain
7Biochemistry Department, University Hospital of Salamanca, Salamanca, ESP
8Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC), Spain, Spain
9Hospital Duran i Reynals, Barcelona, Spain
10Clinical Hematology Department, Institut Català d'Oncologia-L'Hospitalet, IDIBALL, Universitat de Barcelona, Barcelona, Spain
11Hospital de Sant Pau, Hematology Department, Autonomous University of Barcelona, Barcelona, Spain
12Blood Cell Barcelona Hematology Institute, Barcelona, Spain
13Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
14Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC), Madrid, Spain
15Bellvitge Health Sciences Campus, University of Barcelona, Barcelona, Spain
16EBMT Lymphoma Working Party, Paris, France
17Clinical Hematology Department, Institut Català d’Oncologia – L’Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain
18Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France
19Spanish CETLAM group, Spain, Spain
20Haematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain
21Dana-Farber Cancer Institute, Boston, MA
22Institut Josep Carreras and Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Barcelona, Spain
23Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Baldona, Barcelona, Spain
24Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
25Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain
26Hematopoietic Cell Transplantation Unit, Hospital Clínic de Barcelona, ICHMO, Barcelona, Spain
27Hematology Department, Hospital Clinic de Barcelona and Insitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
28Amyloidosis and Multiple Myeloma Unit, Department of Hematology, IDIBAPS, Hospital Clinic, Barcelona, Spain
29Hospital Clinic de Barcelona and Insitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
30Hematology, Institut d'Oncologia Dr. Josep Trueta, Girona, Spain
31Institut Català d'Oncologia Girona, Girona, Spain
32Hematology Department, Hospital Universitario Son Llàtzer. IdIsBa., Palma de Mallorca, Spain
33Hematology, University Hospital Cabueñes, Gijón, Spain
34Hospital Universitario de Canarias, La Laguna, ESP
35Hematology, Hospital Central de Asturias, Oviedo, Spain
36Servicio de Hematología, Hospital Universitario Central de Asturias, Oviedo, Spain
37Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain
38Hematology, Hospital Universitario Ramón y Cajal, Madrid, Spain
39Hematology, Hospital Universitario Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain
40Hematology, Hospital General Universitario de Toledo, Toledo, Spain
41Hematology, IMIB-Virgen de la Arrixaca University Hospital, University of Murcia, El Palmar, Murcia, Spain
42Universidad CEU San Pablo, Madrid, Spain
43Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
44University of Complutense, Hospital 12 de Octubre, Madrid, Spain
45Department of Hematology, Hospital Universitario 12 de Octubre, CNIO, Universidad Complutense de Madrid, Madrid, Spain
46Hematology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain
47Hematology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
48Hematology, Hospital Universitario 12 de Octubre, Imas12, CIBERONC, Madrid, Spain
49Amyloidosis and Multiple Myeloma Unit, Department of Hematology, IDIBAPS, Hospital Clinic, Spain, Barcelona, Spain
50Hospital Clinic, IDIBAPS, Barcelona, Spain
51Hematology, Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; and GEM/PETHEMA, Barcelona, Spain
52Hemato-Oncology Program. Cima Universidad de Navarra. IdiSNA., Pamplona, Spain
53Hematology and Cell Therapy Department. Clinica Universidad de Navarra. IdiSNA., Pamplona, Spain
54Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBER-ONC, Pamplona, Spain
55Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain
56Institute of Cancer Molecular and Cellular Biology, University Hospital of Salamanca, Salamanca, Spain
57University of Salamanca, Department of Medicine, Salamanca, Spain
58Complejo Asistencial Universitario de Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain
59Centro de Investigacion Biomedica en Red de Cancer (CIBERONC)., Madrid, Spain

Introduction: In elderly patients (pts) with multiple myeloma (MM), MRD evaluation by NGF has shown to surpass conventional responses to predict patient outcomes with even a higher clinical impact as compared to younger transplant eligible cases. However, integrating MRD into routine clinical practice in these pts can be particularly challenging due to the need of a bone marrow (BM) aspiration. Our study investigates the clinical value of PRD assessed by mass-spec (MS) and MRD by Next Generation Flow in non-transplant eligible pts included in the GEM2017FIT trial.

Patients and methods: GEM2017FIT is an open-label, randomized, phase 3 trial for fit pts with newly diagnosed MM aged between 65 and 80 years. Fitness was assessed with the GAH scale and eligible pts required 42 points. Pts randomly received 18 induction cycles of either VMP-Rd (arm1, control) or KRd (arm 2a) or Dara-KRd in a 1:1:1 ratio; those pts not treated with Dara during induction (arms 1 and 2a) received 4 cycles of consolidation with Dara-Rd. After induction and consolidation, pts were randomized to receive maintenance with Dara-R or observation (after stratification according to the MRD status by NGF). VMP and Rd were administered at conventional doses. In the Kz-based regimens, Kz was given twice weekly at a dose of 36mg/m2 during cycles 1-2 and at 56 mg/m2 from cycle 3 onwards. Dara was initially planned as iv. but subsequently switched to sc, and always administered with the conventional dose and schedule.

The primary endpoint of the study was the rate of MRD negativity post-induction (sensitivity 10-5). Secondary endpoints included standard responses, progression-free survival (PFS) and overall survival (OS). Besides, we have used Quantitative Immunoprecipitation Mass Spectrometry with anti IgG/A/M, total k and total l beads to assess PRD post-induction using the EXENT® Analyzer (The Binding Site, part of Thermo Fisher Scientific).

Results: 230 pts who completed the 18 induction cycles were included in this study and analyzed for the primary endpoint using NGF and MS. Median age was 72 years (64–80), 48% were male, nearly one third had ISS 3 and 12% presented with extramedullary disease.

PRD and MRD status (NGF with a sensitivity of 10-6) were associated with significant differences in PFS (p<0.0001, HR 0.29 and p<0.0001, HR 0.31, respectively). 79.6% of the results were concordant (25.2% [58/230] NGF+MS+, 54.3% [125/230] NGF-MS-) and 20.4% were discordant (8.7% [20/230] NGF-MS+, 11.7% [27/230] NGF+MS-). Taking NGF results as a reference, the negative and positive predictive values of MS were 82% and 74% (p<0.0001), respectively. When comparing PRD and MRD status (NGF-5) similar results were observed (p<0.0001, HR 0.29 [and p=0.0004, HR 0.32, respectively).

When pts were stratified based on their GAH scale score, both PRD and MRD status were associated with significantly different PFS. For pts with GAH 20, the mPFS was not reached (NR) in the PRD- group compared to the PRD+ group (p=0.0021, HR 0.25), and the same result was observed for MRD (p=0.0074, HR 0.31). For patients with GAH >20, the mPFS was NR in the PRD- group compared to 34 months in the PRD+ group (p=0.0064, HR 0.31), and a similar outcome was observed for MRD (p=0.0044, HR 0.31).

We also studied the value of both PRD and MRD according to the pts' cytogenetic risk. Both PRD and MRD were able to stratify pts with different PFS, with clear significance in standard risk pts (PRD: p=0.0049, HR 0.22; MRD: p=0.0051, HR 0.23) and those with del17/del17p/t(4;14)/t(14;16)/Gain/amp1q/del1p (PRD: p=0.0032, HR 0.33; MRD: p=0.0081, HR 0.38). Combining the cytogenetic risk with PRD or MRD status, we observed that PRD negative and standard risk pts had a very favorable outcome (mPFS NR) compared to PRD positive and high-risk pts (mPFS 34 months; p<0.0001 HR 0.12). The same tendency was observed for MRD- and standard risk pts vs MRD+ and high-risk pts (mPFS NR vs 36 months; p<0.0001; HR 0.12).

Conclusions: In this cohort of non-transplant eligible fit elderly pts with newly diagnosed MM, PRD and MRD assessment showed a significant clinical value in terms of PFS, both in the global cohort as well as in different risk groups based on fragility and cytogenetic risk. These findings suggest that the integration of PRD assessment into routine clinical practice may be beneficial for all elderly pts, independently of their specific risk features.

Disclosures: Puig: Pfizer, Sanofi, Amgen, BMS, Janssen, Takeda, and The Binding Site: Honoraria; Pfizer, Sanofi, Amgen, BMS-Celgene, Janssen, and Takeda: Consultancy. Paiva: Bristol Myers Squibb/Celgene, Janssen, Sanofi, and Takeda: Consultancy; Aztra Zeneca, Bristol Myers Squibb/Celgene, EngMab, Roche, Sanofi, and Takeda: Research Funding; Adaptive, Amgen, Becton Dickinson, Bristol Myers Squibb/Celgene, Janssen, Merck, Novartis, Roche, Sanofi and Takeda: Honoraria. Agullo: The Binding Site: Honoraria. Contreras: The Binding Site: Honoraria. Sureda Balari: Janssen: Consultancy; Sanofi: Consultancy; BMS/Celgene: Consultancy; Novartis: Consultancy; Gilead: Consultancy; Takeda: Consultancy. Gonzalez-Calle: Janssen, GSK, Pfizer, BMS: Consultancy, Other: Travel and accommodation, Speakers Bureau. Oriol: Sanofi: Honoraria, Speakers Bureau; Bristol Myers Squibb/Celgene: Honoraria, Speakers Bureau; Pfizer, Amgen, Oncopeptides: Honoraria; GSK: Honoraria, Speakers Bureau; Johnson & Johnson, Janssen: Honoraria, Speakers Bureau. Ocio: Bristol-Myers Squibb: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Regeneron: Honoraria; GSK: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Menarini: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria; Johnson & Johnson - Janssen: Consultancy, Honoraria, Speakers Bureau; Takeda: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Amgen: Consultancy, Honoraria. Rosiñol Dachs: Amgen: Honoraria, Other: Educational lectures; Sanofi: Honoraria, Other: Honoraria for lectures; GSK: Honoraria, Other: Honoraria for lectures; Janssen Pharmaceutica: Honoraria, Other: Honoraria for lectures and meeting travel support; BMS, Takeda, Pfizer, Menarini: Honoraria. González García: Pfizer: Honoraria. Ramirez: Janssen-Cilag, S.A.: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Roche: Consultancy, Honoraria; EUSA Pharma: Honoraria; Abbvie: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Sanofi: Honoraria; Takeda: Consultancy, Honoraria; Incyte: Honoraria; GSK: Honoraria; Pfizer: Consultancy; Gilead: Consultancy; Beigene: Consultancy. Casado Montero: Janssen, Roche, Novartis, BMS, Amgen, Takeda, Pfizer, Incyte, Abbvie, GSK, Sanofi, BeiGene: Consultancy; Janssen, Roche, Novartis, BMS, Amgen, Takeda, Pfizer, Incyte, Abbvie, GSK, Sanofi, BeiGene, Loxo, ELVN: Research Funding; Janssen, Roche, Novartis, BMS, Amgen, Takeda, Pfizer, Incyte, Abbvie, GSK, Sanofi, BeiGene: Honoraria. Perez de Oteyza: Regeneron Pharmaceuticals, Inc.: Research Funding; Roche: Consultancy, Speakers Bureau; Janssen: Consultancy. Gironella: Beigene, GSK, Janssen-Cilag: Consultancy. Martínez-Lopez: Kite: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Incity: Research Funding. Lahuerta Palacios: Janssen: Honoraria; BMS: Honoraria; Sanofi: Honoraria. Bladé: Celgene/Bristol Myers Squibb: Other: Honoraria for lectures; Amgen: Other: Honoraria for lectures; Janssen: Other: Honoraria for lectures; Sanofi: Other: Honoraria for lectures. San-Miguel: MSD: Other: Advisory board; Novartis: Other; Karyopharm: Other: Advisory board; Janssen-Cilag: Other: Advisory board; Haemalogix: Other: Advisory board; GlaxoSmithKline: Other: Advisory board; Celgene: Other: Advisory board; Bristol Myers Squibb: Other: Advisory board; Amgen: Consultancy, Other: Advisory Board ; Abbvie: Consultancy, Other: Advisory Board; Takeda: Other: Advisory board; Regeneron: Other: Advisory board; Roche: Other: Advisory board; Sanofi: Other: Advisory board; SecuraBio: Other: Advisory board. Mateos: Amgen, Takeda, Regeneron: Honoraria; BMS/Celgene, Janssen-Cilag, Sanofi, Abbvie, Stemline, Oncopeptides, GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH